The total number of diagnosed incident cases of liposarcoma in the countries under study will increase by 17% over the 20-year forecast period.
For the year 2022, liposarcoma of the HNTE accounts for 3,374 diagnosed incident cases in the countries under study; liposarcoma of the abdomen and thoracic viscera accounts for 3,282 cases; and liposarcoma of the retroperitoneum accounts for 1,699 cases.
Of the countries considered in this analysis, Germany has the highest incidence of liposarcoma of the HNTE: 0.5 cases per 100,000 per year in 2022.
Approximately 92% of newly diagnosed incident cases of liposarcoma of the HNTE, the abdomen and thoracic viscera, and the retroperitoneum are amenable to resection.
Natasha Nahar, M.P.H., is an associate epidemiologist at Clarivate. She holds a master’s degree in public health from the Tata Institute of Social Sciences in Mumbai and a bachelor’s degree in dental surgery from BVDU Dental College and Hospital in Sangli.
Narendra Parihar, M.P.H., is a principal epidemiologist at Clarivate. His areas of interest are cancer epidemiology, rare disease epidemiology, and targeted therapies in cancer. A former dentist, he earned his M.P.H. from the Tata Institute of Social Sciences in Mumbai.